Tenderwize
Retour à la recherche

Medicinal products with the active ingredient combination cinnarizine and dimenhydrinate (ATC: N07CA22)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Mar 30, 2027 · 214 days left·Open·Supplies
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Arzneimittel mit der Wirkstoffkombination Cinnarizin und Dimenhydrinat (ATC: N07CA22)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No estimated value or framework maximum is provided, making it impossible to assess potential revenue. The contract is...

The buyer explicitly reserves the right to terminate the agreement if exclusive contracts for the same active ingredien...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Supply of finished medicinal products with the active ingredient combination cinnarizine and dimenhydrinate (ATC: N07CA22)
  • Conclusion of non-exclusive discount agreements under §130a Abs. 8 SGB V
Afficher le résumé complet

This notice announces a non-exclusive discount agreement (Rabattvertrag) under §130a Abs. 8 SGB V for finished medicinal products containing the active ingredient combination cinnarizine and dimenhydrinate (ATC: N07CA22). It follows an open-house model, allowing any qualified pharmaceutical company to conclude a standard contract at any time. The contract runs for a maximum of 24 months from the earliest start date (01.06.2025) until 31.05.2027. The notice explicitly states it is not a public procurement under GWB but is published for transparency. No estimated value or framework maximum value is provided. The submission process is unclear: structured data indicates electronic submission is not allowed, but the XML notice mentions the possibility of submitting electronically signed documents via email.

Risques

No estimated value or framework maximum is provided, making it impossible to assess potential revenue. The contract is...

The buyer explicitly reserves the right to terminate the agreement if exclusive contracts for the same active ingredien...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company or consortium of pharmaceutical companies
  • Contract must be signed and returned to the contact address

Administrative

  • Must request and submit participation documents fully completed and signed

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Magdeburg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE258393558

Activité

Health

Lots (1)

LOT-0001

Medicinal products with the active ingredient combination cinnarizine and dimenhydrinate (ATC: N07CA22)

Non-exclusive discount agreements for finished medicinal products with the active ingredient combination cinnarizine and dimenhydrinate (ATC: N07CA22) under an open-house model. Any qualified pharmaceutical company can join at any time. No exclusivity. Contract duration: maximum 24 months, ending 31.05.2027 irrespective of start date. Early termination possible if the health insurance fund (AOK Sachsen-Anhalt) tenders exclusive contracts during the term.

SuppliesEU fundedElectronic submission

Localisation

DEE03, Germany

Durée

2 YEAR

Catégorie

Pharmaceutical products

Date limite

Deadline Mar 30, 2027

Détails de la procédure

Date de publication
09 Apr 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
234181-2025

Documents (1)

Appels d'offres similaires